Tagged with

Switzerland Jörg Storre, General Manager of CSL Vifor Pharma Switzerland, explores the company’s historical legacy and current focus on innovative iron therapies and nephrology. Storre highlights some of his strategic priorities, including improving patient care and access, fostering talent development, and maintaining supply security within a competitive landscape.    When employees…

Switzerland This interview explores the transformative journey of Tillotts Pharma under the leadership of CEO Thomas Tóth von Kiskér, who has guided the company from a small team in 1996 to a global player with a focus on in-house R&D, strategic M&A, and a commitment to patient-centric innovation. Priorities for continued…

Switzerland Marianthi Psaha, President, Head of EMEA for Santen, discusses the company’s journey towards becoming a specialized leader in ophthalmology—highlighting how digital transformation, innovation in myopia treatment, and strategic partnerships are reshaping its impact on eye health across Europe. Psaha delves into the challenges of building awareness of the area’s importance…

Global With the emergence of GLP-1 RA therapies the obesity drug market has taken off and stands to be worth some USD 125.3 billion by 2033. Eli Lilly and Novo Nordisk may lead the charge, but other contenders are looking to get a piece of this lucrative market as the two…

Global Dr Catherine Duggan, CEO of the International Pharmaceutical Federation, lays out how mental health systems must shift from reactive crisis intervention to proactive, patient-centered approaches; why traditional care models need reimagined funding that prioritises community mental health services and incentivises innovation; and the vital role that pharmacists, as accessible healthcare…

Switzerland Dr Isabelle Dahinden, General Manager of CSL Behring Switzerland, introduces the company’s unique history and strategic focus on plasma-derived treatments. Dr. Dahinden also discusses CSL Behring’s strong presence in Switzerland, including their extensive R&D, production capabilities, and partnerships, while touching on the challenges of navigating the Swiss healthcare landscape.  …

Switzerland Europe and Canada (EUCAN) have an essential role in Takeda’s global mission to advance healthcare innovation. Ricardo Marek, President of Takeda’s EUCAN division, discusses the operational and regulatory challenges, the importance of Switzerland as a strategic base, and Takeda’s post-Shire acquisition growth strategy.   Europe is central not just as…

Switzerland Fabrice Véricel and Geoffrey Folie explore UCB’s strategic growth, highlighting its European sites in Braine-l’Alleud, Belgium and Bulle, Switzerland and their roles in global pharmaceutical production. Key topics include the transition to biologics, embracing AI for process optimization, and sustainability initiatives.   Biomanufacturing thrives on complexity and collaboration, offering intellectual…

Switzerland Jérôme Garcin, newly appointed General Manager of Bristol-Myers Squibb (BMS) Switzerland, shares his journey to the role and discusses the strategic importance of the Swiss affiliate within the global BMS network. In this interview, he highlights BMS’s focus on innovation across therapeutic areas such as oncology, hematology, cardiology and neurology,…

Switzerland Giuseppe Grossi, General Manager of Daiichi Sankyo Switzerland, delves into the company’s strategic growth in cardiovascular and oncology, its commitment to innovation, and its dedication to making a meaningful impact in the Swiss healthcare landscape. Grossi highlights the importance of talent development, adaptability, and a focus on both local and…

Switzerland Anne Mette Wiis Vogelsang, CVP & General Manager of Novo Nordisk Switzerland, discusses Switzerland’s progressive healthcare landscape while addressing key issues like diabetes care, obesity, and systemic healthcare challenges. Vogelsang also calls for increased prioritization of a holistic approach to health, highlighting the importance of primary and secondary prevention, early…

Switzerland Bachem’s Thomas Meier highlights the company’s pivotal role as a CDMO in the rapidly evolving peptide and oligonucleotide markets, emphasizing strategic expansions, innovative manufacturing techniques, and a deep commitment to sustainability. With a vision for growth that includes both profitability and operational excellence, Bachem is poised to lead in therapeutic…